- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00796484
Safety Study of Pharmacokinetics of XL888 in Adults With Solid Tumors
19 augusti 2015 uppdaterad av: Exelixis
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL888 in Subjects With Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of XL888 in subjects with solid tumors.
XL888 is a potent and selective inhibitor of HSP90, a key component of a molecular chaperone complex that promotes the conformational maturation and stabilization of diverse client proteins.
Many HSP90 client proteins play critical roles in signaling pathways implicated in tumor cell growth, proliferation, and survival.
Studieöversikt
Studietyp
Interventionell
Inskrivning (Faktisk)
33
Fas
- Fas 1
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna, 19104
- Hospital of the University of Pennsylvania Abramson Cancer Center
-
-
Texas
-
San Antonio, Texas, Förenta staterna, 78229
- South Texas Accelerated Research Therapeutics
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år och äldre (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- Subject has a histologically-confirmed tumor that is metastatic or unresectable and is no longer responding to therapies known to prolong survival or to other standard therapies, or has disease for which no effective therapy exists.
For subjects enrolling in the maximum tolerated dose expansion cohorts:
- Subject has documented evidence of Her2-overexpressing tumor; OR
- Subject has NSCLC that has progressed after a prior response to erlotinib or gefitinib; OR
- Subject has histologically-confirmed, metastatic melanoma.
- For subjects in the expansion cohorts A and C: tumor tissue must be accessible for biopsy and subjects must be willing to undergo tumor biopsy.
- The subject is ≥ 18 years old.
- The subject has an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.
- The subject's weight is ≥ 40 kg.
- The subject has adequate organ and marrow function.
- The subject is capable of understanding and complying with the protocol requirements and has signed the informed consent document.
- Sexually active subjects (male and female) must use accepted methods of contraception during the course of the study and for 3 months after the last dose of XL888.
- Female subjects of childbearing potential must have a negative pregnancy test at screening.
Exclusion Criteria:
- The subject has received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic therapy (cytokines, antibodies) within 3 weeks (or nitrosoureas or mitomycin C within 6 weeks) before the first dose of XL888.
- The subject has received prior treatment with a small molecule kinase inhibitor (including an investigational kinase inhibitor) or hormonal therapy within 14 days before the first dose of XL888.
- The subject has received any other type of investigational agent within 28 days before the first dose of study treatment.
- The subject has a previously-identified allergy or hypersensitivity to components of the study treatment formulation.
- The subject has not recovered from clinically-meaningful toxicity due to prior therapy.
- The subject has been previously treated with an HSP90 inhibitor
- The subject has untreated or uncontrolled brain metastases or evidence of leptomeningeal involvement of disease.
- The subject is currently receiving anticoagulation with therapeutic dose of warfarin.
- The subject has uncontrolled intercurrent illness including, but not limited to: ongoing or active infection; diabetes mellitus; hypertension; symptomatic congestive heart failure, unstable angina pectoris, stroke or myocardial infarction within 3 months.
- The subject has a baseline corrected QT interval (QTc) > 460 ms.
- The subject is pregnant or breastfeeding.
- The subject is known to be positive for the human immunodeficiency virus (HIV).
- The subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee.
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: 1
|
Administered orally
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Safety, tolerability, and maximum tolerated dose of oral administration of XL888 when administered on an intermittent schedule to adults with solid tumors
Tidsram: Assessed at several visits during weeks 1 through 4 of the first cycle and approximately every other week each cycle thereafter
|
Assessed at several visits during weeks 1 through 4 of the first cycle and approximately every other week each cycle thereafter
|
Plasma pharmacokinetics of oral administration of XL888 when administered on an intermittent schedule
Tidsram: Assessed at several visits during weeks 1 through 4 of the first cycle and approximately once every four weeks each cycle thereafter
|
Assessed at several visits during weeks 1 through 4 of the first cycle and approximately once every four weeks each cycle thereafter
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
Pharmacodynamic effects of XL888 on both tumor tissue and non-tumor tissue
Tidsram: Assessed at specific visits during the first cycle; mandatory blood samples collected once every four weeks every cycle thereafter with optional tissue samples
|
Assessed at specific visits during the first cycle; mandatory blood samples collected once every four weeks every cycle thereafter with optional tissue samples
|
Estimate renal elimination of XL888
Tidsram: Assessed during the first cycle after three weeks of dosing
|
Assessed during the first cycle after three weeks of dosing
|
Exploratory: To evaluate preliminary antitumor activity of XL888
Tidsram: Assessed every eight weeks
|
Assessed every eight weeks
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 november 2008
Primärt slutförande (Faktisk)
1 november 2010
Avslutad studie (Faktisk)
1 november 2010
Studieregistreringsdatum
Först inskickad
20 november 2008
Först inskickad som uppfyllde QC-kriterierna
21 november 2008
Första postat (Uppskatta)
24 november 2008
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
21 augusti 2015
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
19 augusti 2015
Senast verifierad
1 augusti 2015
Mer information
Termer relaterade till denna studie
Nyckelord
Andra studie-ID-nummer
- XL888-001
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på XL888
-
Emory UniversityNational Cancer Institute (NCI); Merck Sharp & Dohme LLC; National Institutes... och andra samarbetspartnersAvslutadOoperabelt pankreascancer | Metastaserande bukspottkörteladenokarcinom | Återkommande pankreascancer | Steg III Bukspottkörtelcancer | Steg IV Bukspottkörtelcancer | Återkommande kolorektalt karcinom | Kolorektalt adenokarcinom | Steg IV Kolorektal cancer | Steg IVA kolorektal cancer | Steg IVA Pankreascancer och andra villkorFörenta staterna
-
Access Pharmaceuticals, Inc.Advanced Clinical Research Services, LLCAvslutad
-
H. Lee Moffitt Cancer Center and Research InstituteGenentech, Inc.; ExelixisAktiv, inte rekryterandeMelanom | HudcancerFörenta staterna
-
H. Lee Moffitt Cancer Center and Research InstituteExelixisAvslutadStudie av XL888 med Vemurafenib för patienter med icke-operabelt BRAF-muterat stadium III/IV-melanomMelanomFörenta staterna